Metallothionein I as a direct link between therapeutic hematopoietic stem/progenitor cells and cerebral protection in stroke

National Institutes of Health/National Heart, Lung, and blood Institute (NIH/NHLBI (HL125572-01A1)); Malcolm Feist Cardiovascular Fellowship program; National Institute of General Medical Sciences COBRE Grant (P30- GM110703) and Japan Society for the Promotion of Science (Grants-in-Aid for Scientific Research- KAKENHI, 16H07356)

Targeting AnxA1/Fpr2/ALX Regulates Neutrophil Function Promoting Thrombo-Inflammation Resolution in Sickle Cell Disease

NIH/NHLBI (HL134959-01A1 [FNEG]; HL098435, HL133497, HL141155, and GM12130 [AWO]; HL142604 [RP]), the AHA (19PRE34380751 [ZAY]) and the Royal Society Wolfson Foundation (RSWF\R3\183001 [FNEG])

Targeting AnxA1/Formyl Peptide Receptor 2 Pathway Affords Protection against Pathological Thrombo-Inflammation

© 2020 by the authors. Stroke is a leading cause of death and disability globally and is associated with a number of co-morbidities including sepsis and sickle cell disease (SCD). Despite thrombo-inflammation underlying these co-morbidities, its pathogenesis remains complicated and drug discovery programs aimed at reducing and resolving the detrimental effects remain a major therapeutic challenge. The objective of this study was to assess whether the anti-inflammatory pro-resolving protein Annexin A1 (AnxA1) was able to reduce inflammation-induced thrombosis and suppress platelet activation and thrombus formation in the cerebral microvasculature. Using two distinct models of pathological thrombo-inflammation (lipopolysaccharide (LPS) and sickle transgenic mice (STM)), thrombosis was induced in the murine brain using photoactivation (light/dye) coupled with intravital microscopy. The heightened inflammation-induced microvascular thrombosis present in these two distinct thrombo-inflammatory models was inhibited significantly by the administration of AnxA1 mimetic peptide AnxA1Ac2-26 (an effect more pronounced in the SCD model vs. the endotoxin model) and mediated by the key resolution receptor, Fpr2/ALX. Furthermore, AnxA1Ac2-26 treatment was able to hamper platelet aggregation by reducing platelet stimulation and aggregation (by moderating αIIbβ3 and P-selectin). These findings suggest that targeting the AnxA1/Fpr2/ALX pathway represents an attractive novel treatment strategy for resolving thrombo-inflammation, counteracting e.g., stroke in high-risk patient cohorts.The American Heart Association, grant number 16IRG27790071; Royal Society Wolfson Foundation, grant number RSWF\R3\183001 (FNEG)

Novel Role of T Cells and IL-6 (Interleukin-6) in Angiotensin II–Induced Microvascular Dysfunction

National Institutes of Health/National Heart, Lung, and Blood Institute; Louisiana State University Health Science CenterNational Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI [HL134959-01A1]); Malcolm Feist Cardiovascular Endowment fund at Louisiana State University Health Science Center